Objective: To determine the effectiveness of the nutritional supplement developed for the Oportunidades programme on growth, prevalence of anaemia, morbidity and cognitive function of pre-school children.

Design: In a randomised, placebo-controlled longitudinal trial, children were assigned to one of three experimental treatment groups: Oportunidades food supplement (OFS), powdered milk (PM) and placebo (PL). Treatments were administered daily for 6 months. Weight, height and Hb were measured in all participants before and after supplementation. Morbidity was assessed two times per week for 6 months using validated questionnaires. The Bayley Scale of Infant Development Test was administered at baseline and after 6 months.

Setting: Three marginal rural communities of the state of Queretaro, Mexico.

Subjects: A total of 224 children, mean age 22·4 (SD 5·9) months, were recruited. After the 6-month intervention, 186 completed the study.

Results: No differences were found in the adjusted changes of weight, height or anaemia between treatment groups and PL. No differences were found in the number of episodes of gastrointestinal or respiratory disease, nor were there any differences in cognitive performance between treatment and PL groups after 6 months of supplementation.

Conclusions: Daily supplementation of 12-24-month-old children with OFS has no additional benefits in growth, anaemia, morbidity or cognitive performance.

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1368980010003344DOI Listing

Publication Analysis

Top Keywords

anaemia morbidity
12
morbidity cognitive
12
treatment groups
12
effectiveness nutritional
8
nutritional supplement
8
oportunidades programme
8
programme growth
8
growth anaemia
8
weight height
8
cognitive performance
8

Similar Publications

Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co-morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.

View Article and Find Full Text PDF

Frequency and Distribution of Parasites Detected in Children Between 2017-2022 (6-year Period).

Turkiye Parazitol Derg

January 2025

Sağlık Bilimleri Üniversitesi, Dr. Behçet Uz Çocuk Hastalıkları ve Cerrahisi Eğitim Araştırma Hastanesi, Mikrobiyoloji Laboratuvarı, İzmir, Türkiye.

Objective: In the study, various complaints such as gastrointestinal complaints such as diarrhea, constipation, abdominal pain, nausea and vomiting, weight loss, night urination, itching around the anus, malnutrition, malabsorption, anemia, intelligence and developmental delay were reported to University of Health Sciences Türkiye, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Researhc Hospital, Microbiology Laboratory between 2017 and 2022. It was aimed to determine the frequency and distribution of intestinal parasites in patients presenting with clinical symptoms.

View Article and Find Full Text PDF

Background: The Sustainable Development Goals Target 2.2 aims to eliminate all forms of malnutrition, including anemia, while the World Health Assembly targets a 50% reduction in anemia among women of childbearing age by 2025. Despite these efforts, global anemia prevalence among women has only slightly decreased from 31% to 30% between 2000 and 2019.

View Article and Find Full Text PDF

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Nat Med

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.

Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!